| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CRITREVONC.2015.08.011 |
| P698 | PubMed publication ID | 26318092 |
| P50 | author | Ana Lluch | Q67755317 |
| J Pérez Fidalgo | Q73857902 | ||
| Paloma Martín Martorell | Q78511506 | ||
| P2093 | author name string | Joan Albanell | |
| Miguel Martín | |||
| María Teresa Martínez | |||
| Begoña Bermejo | |||
| Juan Miguel Cejalvo | |||
| Vanesa Pons | |||
| P2860 | cites work | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 96-106 | |
| P577 | publication date | 2015-08-11 | |
| P1433 | published in | Critical Reviews in Oncology Hematology | Q15724423 |
| P1476 | title | Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature | |
| P478 | volume | 97 |
| Q38824661 | Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling |
| Q54986604 | Activating HER2 mutations as emerging targets in multiple solid cancers. |
| Q39018742 | Adjuvant trastuzumab: a 10-year overview of its benefit. |
| Q57170022 | Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review |
| Q52714655 | Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine. |
| Q46216419 | Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells. |
| Q42362796 | Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study. |
| Q38661390 | Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. |
| Q26752780 | Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| Q28072513 | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
| Q37580443 | Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study |
| Q36764627 | Prognostic and Predictive Values of Subcellular Localisation of RET in Renal Clear-Cell Carcinoma |
| Q57109788 | Progress in targeted therapy for breast cancer |
| Q58778783 | STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer |
| Q95661084 | The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy |
| Q28079391 | Twenty years of anti-HER2 therapy-associated cardiotoxicity |
| Q37634220 | Understanding breast cancer - The long and winding road |
Search more.